Institute of Cancer Research; Royal Cancer Hospital (The)
发明人:
ASHWORTH, Alan,LORD, Christopher James,ELLIOTT, Richard James Rowland,NICULESCU-DUVAZ, Dan,PORTER, Roderick,BOFFEY, Raymond John,BAYFORD, Melanie Jayne,FIRTH-CLARK, Stuart,JARVIS, Ashley Nicholas,PERR
申请号：
ES13709994
公开号：
ES2611504T3
申请日:
2013.03.07
申请国别(地区):
ES
年份:
2017
代理人:
摘要：
A compound selected from the compounds of the following formula and pharmaceutically acceptable salts, N-oxides, hydrates and solvates thereof: ** Formula ** in which: W is CRW, X is CRX, Y is CRY and Z is CRZ ("phenyl")； or W is N, X is CRX, Y is CRY and Z is CRZ ("pyrid-2-yl")； or W is CRW, X is N, Y is CRY and Z is CRZ ("pyrid-3-yl")； or W is N, X is CRX, Y is CRY and Z is N ("pyrimidin-2-yl")； or W is CRW, X is N, Y is N and Z is CRZ ("pyrimidin-5-yl")； or W is N, X is CRX, Y is N and Z is CRZ 15 ("pyrazin-2-yl")； or W is N, X is N, Y is CRY and Z is CRZ ("pyridazin-3-yl")； in which: -RW is independently -H or -RWW； -RX is independently -H or -RXX； -RY is independently -H or -RYY； and -RZ is independently -H or -RZZ； wherein: -RWW is independently -X1, -R1, -OH, -OR1, -CF3 or -OCF3； -RXX is independently -X1, -R1, -OH, -OR1, -CF3 or -OCF3； -RYY is independently -X1, -R1, -OH, -OR1, -CF3 or -OCF3； and -RZZ is independently -X1, -R1, -OH, -OR130, -CF3 or -OCF3； wherein: each -X1 is independently -F, -Cl, -Br or -I； and each -R1 is independently saturated, linear or branched C1-4 alkyl； and in which: - L3P- is independently a single covalent bond or -L3PL-； in which: - L3PL- is independently -L3PR1-, -C (>； = O) -, -L3PR2-C (>； = O) -, -S (>； = O) 2-, - L3PR3-S (>； = O) 2- or -O-L3PR4-； wherein: each -L3PR1- is saturated, linear or branched C1-4 alkylene； each -L3PR2- is saturated, linear or branched C1-4 alkylene； each -L3PR3- is saturated, linear or branched C1-4 alkylene； each -L3PR4- is saturated, linear or branched C1-4 alkylene； and wherein: - R3N is independently -NH2, -NHRA, -NRARB or -NRCRD； in which: each -RA is independently: - RA1 -RA2 -RA3 -RA4, -RA5, -LA-RA2, -LA-RA3, 5 -LA-RA4 or -LA-RA5； each -RA1 is saturated, linear or branched C1-6 alkyl, and is optionally substituted with one or more -RS1 groups； each -RA2 is saturated C3-6 cycloalkyl, and is optionally substituted with one or more -RS2C groups； each -RA3 is non-aromatic C3-7 heterocycly
